MK-677 vs Ipamorelin
Comparing oral ghrelin agonism with injectable GH secretagogue signaling
Comparison summary
Overview
MK-677 vs Ipamorelin compares two GH-axis compounds that both connect to endogenous growth-hormone stimulation but differ in route, mechanism emphasis, and evidence framing.
Mechanism comparison
This comparison focuses on ghrelin-receptor signaling, endocrine output, and practical differences between an oral compound and an injectable secretagogue.
Research comparison
The evidence should be weighed by human GH/IGF-1 data, body-composition outcomes, and monitoring considerations.
MK-677
Peptide
Type
ghrelin receptor agonist
Overview
MK-677 is a non-peptide ghrelin receptor agonist studied for GH and IGF-1 stimulation.
Clinical context
Users compare these compounds in hormone optimization, body recomposition, and GH-axis support contexts.
Use case comparison
The most relevant lens is hormone optimization, but route of administration and evidence maturity also matter.
Safety considerations
Both compounds can affect GH/IGF-1 signaling and may require monitoring for edema, appetite, and glucose-related changes.
Peptides studied
Stack studied
Ghrelin Drive Stack
Performance Stack
GH Optimization Stack
Related studies
Bottom line
MK-677 offers oral delivery and human data, while ipamorelin is more clearly positioned as a selective injectable secretagogue.